thromboxane-b2 has been researched along with luzindole* in 1 studies
1 other study(ies) available for thromboxane-b2 and luzindole
| Article | Year |
|---|---|
Agomelatine inhibits platelet aggregation through melatonin receptor-dependent and independent mechanisms.
Melatonin is known to inhibit platelet aggregation induced by arachidonic acid (AA). In the present study we investigated whether agomelatine (Ago), an antidepressant with agonist activity at melatonin receptor 1 (MT1) and MT2 could reduce platelets aggregation and adhesion.. Human platelets from healthy donors were used to test the in vitro effects of Ago in the presence of different platelet activators. We performed aggregation and adhesion assays, thromboxane B. The present data show that Ago suppresses human platelet aggregation and suggest that this antidepressant may have the potential to prevent atherothrombotic ischemic events by reducing thrombus formation and vessel occlusion. Topics: Antidepressive Agents; Blood Platelets; Calcium; Collagen; Humans; Platelet Aggregation; Receptors, Melatonin; Thromboxane B2; Thromboxanes | 2023 |